Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer

Multiple drug resistant (MDR) malignancy remains a predictable and often terminal event in cancer therapy, and affects individuals with many cancer types, regardless of the stage at which they were originally diagnosed or the interval from last treatment. Protein biomarkers of MDR are not globally u...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Gerald, Lobanova, Liubov, Dawicki, Wojciech, Groot, Gary, Gordon, John R., Bowen, Matthew, Harkness, Troy, Arnason, Terra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718420/
https://www.ncbi.nlm.nih.gov/pubmed/29211738
http://dx.doi.org/10.1371/journal.pone.0187191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718420/
https://www.ncbi.nlm.nih.gov/pubmed/29211738
http://dx.doi.org/10.1371/journal.pone.0187191

Ejemplares similares